Insmed Inc (INSM) - Total Liabilities
Based on the latest financial reports, Insmed Inc (INSM) has total liabilities worth $1.42 Billion USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore INSM net assets growth trend to track the company's year-over-year net asset growth rate.
Insmed Inc - Total Liabilities Trend (1999–2024)
This chart illustrates how Insmed Inc's total liabilities have evolved over time, based on quarterly financial data. See free cash flow generation of Insmed Inc to measure how efficiently the company converts operating cash flow to free cash.
Insmed Inc Competitors by Total Liabilities
The table below lists competitors of Insmed Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Naver Corporation
KO:035420
|
Korea | ₩12.13 Trillion |
|
SharkNinja, Inc.
NYSE:SN
|
USA | $2.26 Billion |
|
Bank of Nanjing Co Ltd
SHG:601009
|
China | CN¥2.99 Trillion |
|
Affirm Holdings Inc
NASDAQ:AFRM
|
USA | $9.36 Billion |
|
Guangdong Dtech Technology Co. Ltd. A
SHE:301377
|
China | CN¥2.43 Billion |
|
AMADEUS IT GRP ADR EO-001
F:AI3B
|
Germany | €6.62 Billion |
|
China Northern Rare Earth Group High-Tech Co Ltd
SHG:600111
|
China | CN¥18.61 Billion |
|
Helvetia Holding AG
SW:HBAN
|
Switzerland | CHF132.70 Billion |
Liability Composition Analysis (1999–2024)
This chart breaks down Insmed Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Insmed Inc (INSM) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.63 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.50 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.60 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Insmed Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Insmed Inc (1999–2024)
The table below shows the annual total liabilities of Insmed Inc from 1999 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.74 Billion | +4.70% |
| 2023-12-31 | $1.66 Billion | +5.95% |
| 2022-12-31 | $1.57 Billion | +88.28% |
| 2021-12-31 | $833.04 Million | +60.12% |
| 2020-12-31 | $520.27 Million | +8.25% |
| 2019-12-31 | $480.62 Million | +21.28% |
| 2018-12-31 | $396.29 Million | +292.41% |
| 2017-12-31 | $100.99 Million | +20.98% |
| 2016-12-31 | $83.47 Million | +86.08% |
| 2015-12-31 | $44.86 Million | +0.52% |
| 2014-12-31 | $44.63 Million | +34.52% |
| 2013-12-31 | $33.17 Million | +1.51% |
| 2012-12-31 | $32.68 Million | +487.12% |
| 2011-12-31 | $5.57 Million | +62.65% |
| 2010-12-31 | $3.42 Million | +23.05% |
| 2009-12-31 | $2.78 Million | -63.32% |
| 2008-12-31 | $7.58 Million | -5.38% |
| 2007-12-31 | $8.01 Million | -44.62% |
| 2006-12-31 | $14.47 Million | +17.24% |
| 2005-12-31 | $12.34 Million | +113.66% |
| 2004-12-31 | $5.78 Million | +60.80% |
| 2003-12-31 | $3.59 Million | -26.09% |
| 2002-12-31 | $4.86 Million | -59.20% |
| 2001-12-31 | $11.91 Million | +100.66% |
| 2000-12-31 | $5.94 Million | +611.80% |
| 1999-12-31 | $833.94K | -- |
About Insmed Inc
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antiba… Read more